Vermillion's Q4 OVA1 Sales Grow 40 Percent | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Vermillion said after the close of the market on Thursday that fourth quarter OVA1 volume increased 40 percent year over year in preliminary results, while license revenues fell 42 percent.

Results for the quarter and for full-year 2011 are still subject to change as the company awaits a 2011 report from strategic partner Quest Diagnostics and a ruling in an arbitration case involving Molecular Analytical Systems, it said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: miR-515 levels higher in women with preeclampsia, horizontal gene transfer in parasitic plants, and more.

A cancer researcher retracts 19 articles from one journal for image manipulation, according to Retraction Watch.

Precision medicine has to consider context in addition to genetic mutations in cancer treatment, Medscape reports.

Genomics may help the Cavendish banana from succumbing to fungal infections, a trio of researchers writes at the Conversation.